"For the first time, clinicians have a tool to objectively understand where a child is on the spectrum, reach a diagnosis, and deliver personalized care," says EarliTec CEO Tom Ressemann in a press release about the company's EarliPoint Evaluation, a first-of-its-kind autism test that's been approved by the FDA.
The Atlanta-based company has just announced a $21.5 million Series B financing round, per a press release, which will be used to expand commercialization efforts and advance clinical research for the device, which tracks a child's moment-by-moment looking behavior at the rate of 120 times per second, which is "otherwise imperceptible to the human eye," per the press release.
The device is currently used to diagnose autism in children between 16 months and 30 months, and the FDA has approved it for use with children ages 3 to 7.
"There is a severe unmet need in autism diagnosis, and families often face a challenging path to diagnosis of autism due to the lack of innovation in the space and limited access to expert clinicians," Dr. Ami Klin, chief clinical officer and founder of EarliTec, says in the press release.
"EarliPoint represents a meaningful step forward in better, accessible
Read the Entire Article
A customized collection of news from foundations from around the Web.
HootSuite CEO Ryan Holmes says “…social tools are getting more broadly adopted across organizations. It’s not just marketing anymore, it’s sales, public relations, human relations, everywhere.”